Bo Yi
Bo Yi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Anna Zhang
School of Medicine, Shanghai University, Shanghai, China
1 shared publicationBaoyan Wang
1 shared publication- Bingmiao Gao
School of Pharmaceutical Sciences, Hainan Medical University, Haikou 571199, China
1 shared publication Cheng Xue
1 shared publicationGuojun Chu
Department of Cardiology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China
1 shared publicationGuoling Yang
School of Medicine, Shanghai University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 16 September 2026
- Published by Tsinghua University Press in Food Science and Human Wellness
Multi-target ocular protection of blueberry anthocyanins in elderly type 2 diabetes: An exploratory clinical investigation
With the increasing prevalence of diabetic retinopathy (DR), there is an urgent need for interventions offering both metabolic and ocular benefits. This initial clinical exploration investigated the intervention effects of blueberry anthocyanins in elderly type 2 diabetic patients over six months. Supplementation with blueberry anthocyanin extract (BAE, 400 mg/day) showed favorable changes in ocular functions, with improved visual acuity (as reflected by negative ΔlogMAR values), reduced intraocular pressure (IOP∼8%, P < 0.05), and restored retinal structural integrity, which was evidenced by decreased macular edema and retinal thickness via optical coherence tomography (OCT) imaging. Furthermore, patients reported a notable alleviation of visual fatigue symptom, such as eye soreness (P < 0.05) and lacrimation (P < 0.01). Correlating with the observed ocular protection, BAE also improved systemic metabolic parameters such as fasting blood glucose and glycated hemoglobin (HbA1c) (P < 0.01), insulin resistance (triglyceride-glucose index), and inflammation markers (such as neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio). These findings should be interpreted as preliminary associations, as concurrent medications were not systematically controlled. Nonetheless, they tentatively indicated the dual action of blueberry anthocyanins for simultaneously targeting metabolic dysregulation and DR-associated visual impairment, providing clinical evidence for its development as a promising functional food used in adjunct therapy for diabetic patients.
- 16 September 2026
- Published by Tsinghua University Press in Food Science and Human Wellness
Open AccessMulti-target ocular protection of blueberry anthocyanins in elderly type 2 diabetes: An exploratory clinical investigation
With the increasing prevalence of diabetic retinopathy (DR), there is an urgent need for interventions offering both metabolic and ocular benefits. This initial clinical exploration investigated the intervention effects of blueberry anthocyanins in elderly type 2 diabetic patients over six months. Supplementation with blueberry anthocyanin extract (BAE, 400 mg/day) showed favorable changes in ocular functions, with improved visual acuity (as reflected by negative ΔlogMAR values), reduced intraocular pressure (IOP∼8%, P < 0.05), and restored retinal structural integrity, which was evidenced by decreased macular edema and retinal thickness via optical coherence tomography (OCT) imaging. Furthermore, patients reported a notable alleviation of visual fatigue symptom, such as eye soreness (P < 0.05) and lacrimation (P < 0.01). Correlating with the observed ocular protection, BAE also improved systemic metabolic parameters such as fasting blood glucose and glycated hemoglobin (HbA1c) (P < 0.01), insulin resistance (triglyceride-glucose index), and inflammation markers (such as neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio). These findings should be interpreted as preliminary associations, as concurrent medications were not systematically controlled. Nonetheless, they tentatively indicated the dual action of blueberry anthocyanins for simultaneously targeting metabolic dysregulation and DR-associated visual impairment, providing clinical evidence for its development as a promising functional food used in adjunct therapy for diabetic patients.
- 8 May 2026
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 393 (6) , 104938
Artesunate does not prevent cardiac hypertrophy but inhibits heart failure progression in mice
- 8 May 2026
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 393 (6) , 104938
Artesunate does not prevent cardiac hypertrophy but inhibits heart failure progression in mice
- Open Access
- 26 February 2026
- Published by MDPI AG in Marine Drugs
- Vol. 24 (3) , 92
Crude Venom from Sea Anemone Macrodactyla doreensis Suppresses Glioblastoma via the p53 Pathway
Glioblastoma is a highly invasive primary brain tumor with a poor prognosis, highlighting the need for new therapeutic strategies. Toxins derived from Macrodactyla doreensis have attracted attention for their potential anticancer activity. This study evaluated the anticancer and cytotoxic effects of M. doreensis crude venom on two commonly used glioblastoma cell lines (U251 and LN229), which mirror the phenotype of primary tumors. Cell viability and proliferation were assessed using the CCK-8 assay and colony formation assay, while cell migration and invasion capabilities were detected via wound healing assay and Transwell assay. Annexin V/PI staining and PI-based cell cycle analysis indicated that the crude venom significantly induced cell apoptosis and caused S-phase arrest. Proteomic analysis combined with GO and KEGG enrichment analyses as well as bioinformatics approaches showed that M. doreensis crude venom inhibits glioblastoma cell proliferation by downregulating the expression of CDK2, RRM2, and CHEK1, thereby hindering cell cycle progression and regulating the p53 signaling pathway. Notably, the downregulation of these key glioblastoma-related target genes was validated by qPCR. In addition, network pharmacology analysis indicated that several peptide families present in the sea anemone crude venom, including ShK peptides, inhibitor cystine knot (ICK) peptides, and EGF-like peptides, exhibit notable antitumor potential. Combined with AlphaFold2-based structural modeling and molecular docking, these analyses further elucidated the potential molecular mechanisms underlying their interactions with key targets, such as MD-381 with RRM2, MD-322 with CDK2, and MD-429 with CHEK1. Collectively, these findings highlight the therapeutic potential of M. doreensis crude venom and lay a foundation for the subsequent isolation of novel peptides and their further development in glioblastoma treatment.
- 26 February 2026
- Published by MDPI AG in Marine Drugs
- Vol. 24 (3) , 92
Open AccessCrude Venom from Sea Anemone Macrodactyla doreensis Suppresses Glioblastoma via the p53 Pathway
Glioblastoma is a highly invasive primary brain tumor with a poor prognosis, highlighting the need for new therapeutic strategies. Toxins derived from Macrodactyla doreensis have attracted attention for their potential anticancer activity. This study evaluated the anticancer and cytotoxic effects of M. doreensis crude venom on two commonly used glioblastoma cell lines (U251 and LN229), which mirror the phenotype of primary tumors. Cell viability and proliferation were assessed using the CCK-8 assay and colony formation assay, while cell migration and invasion capabilities were detected via wound healing assay and Transwell assay. Annexin V/PI staining and PI-based cell cycle analysis indicated that the crude venom significantly induced cell apoptosis and caused S-phase arrest. Proteomic analysis combined with GO and KEGG enrichment analyses as well as bioinformatics approaches showed that M. doreensis crude venom inhibits glioblastoma cell proliferation by downregulating the expression of CDK2, RRM2, and CHEK1, thereby hindering cell cycle progression and regulating the p53 signaling pathway. Notably, the downregulation of these key glioblastoma-related target genes was validated by qPCR. In addition, network pharmacology analysis indicated that several peptide families present in the sea anemone crude venom, including ShK peptides, inhibitor cystine knot (ICK) peptides, and EGF-like peptides, exhibit notable antitumor potential. Combined with AlphaFold2-based structural modeling and molecular docking, these analyses further elucidated the potential molecular mechanisms underlying their interactions with key targets, such as MD-381 with RRM2, MD-322 with CDK2, and MD-429 with CHEK1. Collectively, these findings highlight the therapeutic potential of M. doreensis crude venom and lay a foundation for the subsequent isolation of novel peptides and their further development in glioblastoma treatment.